November 29, 2010
Bharatbook added a new report on “Advances in Vaccine Technology and Delivery” which gives the growth and development in the Vaccines Market.
Advances in Vaccine Technology and Delivery
A comprehensive 164-page analysis of this fast-growing sector with market projections and extensive company, product and research evaluation of all major vaccine areas.
Key areas addressed by this new January 2010 report…
* Market trends and challenges with projections to 2015 for the major vaccine sectors
* The latest advances in vaccine technologies including DNA vaccines (viral, bacterial, yeast-based and complex DNA) and adjuvants (immune potentiators)
* Novel delivery systems including needle free, liquid jet injectors, solid dose, intranasal, oral and transdermal delivery options
* How a better understanding of immunology is driving the sector ( http://www.bharatbook.com/detail.asp?id=160113&rt=Advances-in-Vaccine-Technology-and-Delivery.html )
* An assessment of current and future vaccines for viral infections including influenza, hepatitis, HIV and herpes
* Emerging disease, biodefence and parasitic disease targets including malaria, Ebola, dengue fever and West Nile virus
* The issues surrounding effective clinical trial design for vaccines Prophylactic vaccines for cervical and gastric cancer
* Therapeutic cancer vaccine research approaches and vaccines under development for 12 cancer types
* A review of novel therapeutic vaccines in key areas such as diabetes, Alzheimer’s disease and allergies.
* The vibrant field of vaccine research will continue to grow and evolve over the next few years and to generate ever increasing revenues as new vaccines reach the market.
Unbeatable coverage and analysis of this high growth market sector…
The advances made in immunology over the past two decades, in conjunction with the growing acceptance of the importance of preventive medicine, have given the field of vaccine research a new lease of life. Vaccines for difficult infectious disease targets, such as Neisseria meningitidis Group B and malaria, may become a reality over the next five to ten years. However, for other difficult and important targets such as HIV and cancer the wait for a vaccine may be longer and will rely on the use of new technologies, including plasmid DNA, adjuvants and delivery systems that are currently in the early stages of development.
Vaccines are attracting significant research attention
The increasing use of novel technologies is reflected in the fact that almost half of the current pipeline of prophylactic vaccines against infectious diseases are in preclinical or Phase I trials. These vaccine candidates have largely been developed by smaller companies emerging from academia, such as Vical, Novavax, Acambis, Coley Pharmaceuticals, Crucell and Intercell, and represent future licensing and acquisition targets. Most of the pharma companies with the highest stakes in the vaccines market – sanofi-aventis, Pfizer, Merck & Co, GlaxoSmithKline and Novartis – have extensive pipelines of vaccine candidates in development based on acquired technology and will be vigilant for the opportunities offered by up-coming companies with promising new platform technologies.
For more information kindly visit : http://www.bharatbook.com/detail.asp?id=160113&rt=Advances-in-Vaccine-Technology-and-Delivery.html
Beverage Packaging Global Summary
The Future of Sustainable Food and Beverage Packaging
Contact us at :bharatbook